HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gerbino, P. P. Articles by Shoheiber, O. Search for Related Content PubMed PubMed Citation Articles by Gerbino, P. P. Articles by Shoheiber, O.

PHILIP P. GERBINO, PHARM. D., is President, University of the Sciences in Philadelphia, Philadelphia, PA. OMAR SHOHEIBER, PHARM.D., is Senior Vice President, Tricore Interactive, Inc., Monmouth Junction, NJ.

Address correspondence to Dr. Gerbino at the University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, PA 19104-4495 (c.lyle{at}usip.edu).

Purpose. Adherence patterns of patients treated with a fixed-dose combination of amlodipine–benazepril versus an angiotensin-converting-enzyme (ACE) inhibitor plus a dihydropyridine calcium-channel blocker (CCB) prescribed as separate drugs were studied. Methods. In this retrospective analysis of pharmacy claims from a managed care organization in the northeastern United States, patients who received at least two prescriptions for fixed-dose amlodipine–benazepril (n = 2839) or at least two prescriptions for an ACE inhibitor plus a dihydropyridine CCB (n = 3367) were followed over one year. Adherence, defined as the medication possession ratio (MPR), was calculated based on daily possession of the prescribed drug or drugs over the study period. To estimate the impact of overall drug burden on adherence to antihypertensive therapy, concomitant medication use was calculated as the number of American Hospital Formulary Service (AHFS) drug classes prescribed. Results. Adherence rates among patients receiving fixed-dose amlodipine–benazepril versus an ACE inhibitor plus a dihydropyridine CCB were 87.9% and 69.2%, respectively (p < 0.0001) over a mean follow-up of 259 and 247 days, respectively. Patients received a mean 4.0 major AHFS drug classes in the amlodipine–benazepril group and 5.2 in the ACE inhibitor plus dihydropyridine CCB group. As the number of concomitant drugs increased, the difference in the MPR between the two treatment groups increased in favor of fixed-dose amlodipine–benazepril. Conclusion. Fixed-dose amlodipine–benazepril was associated with higher adherence rates versus an ACE inhibitor plus a dihydropyridine CCB taken as two separate tablets, regardless of the number of concomitant medications prescribed. Index terms: Amlodipine; Angiotensin-converting-enzyme inhibitors; Benazepril; Calcium antagonists; Combined therapy; Compliance; Drug comparisons; Hypertension; Hypotensive agents; Patients

 

This article has been cited by other articles:

				G. L. Bakris and M. Berkwits Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes Ann Intern Med, March 4, 2008; 148(5): 400 - 401. [Full Text] [PDF]